Senseonics secures coverage from UnitedHealthcare
By HME News Staff
Updated 9:38 AM CDT, Mon June 5, 2023
GERMANTOWN, Md. – Senseonics Holdings has announced that UnitedHealthcare will begin providing coverage for the Eversense E3 CGM System effective July 1, 2023, for people with Type 1 and insulin-requiring Type 2 diabetes. "The policy update from UnitedHealthcare marks an important milestone for increased access to long-term CGM for people with diabetes,” said Tim Goodnow, PhD, president and CEO for Senseonics. “With the addition of UnitedHealthcare, we are nearing all insured adults in the United States having access to the Eversense E3 CGM System. The Eversense E3 CGM System enables patients and health care providers to effectively manage diabetes for six months with sustained accuracy and a removable smart transmitter that provides vibratory alerts and comprehensive data regarding glucose values and trends. We are excited about the expanded opportunity to provide these differentiated benefits of Eversense to more people with diabetes in collaboration with our global commercial partner Ascensia Diabetes Care." This recent coverage decision adds to the extensive number of payers that include Eversense in their CGM coverage policies that now benefit approximately 300 million covered lives, as well as pay for the health care provider's time for in-office sensor insertion.
Comments